Abstract
Commentary: The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension.
Highlights
Pulmonary arterial hypertension (PAH) is a progressive and irreversible lung disease that reduces survival
PAH is categorized as a pulmonary artery pressure greater than 25 mmHg, with various factors contributing to the pathogenesis of the disease, including higher levels of endothelin-1, decreased nitric oxide (NO) synthase expression, and inhibition of the prostacyclin pathway which leads to decreased relaxation and induced proliferation of pulmonary artery smooth muscle cells (PASMCs) (McLaughlin and McGoon, 2006)
The results show that expression levels of sphingosine kinase 1 (SphK1) and S1P were considerably higher in the lungs of patients with PAH and in PH rodent models after exposure to hypoxia (10% O2) for 4 weeks, compared to normoxic control animals
Summary
Pulmonary arterial hypertension (PAH) is a progressive and irreversible lung disease that reduces survival. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension by Chen, J., Tang, H., Sysol, J. PAH is categorized as a pulmonary artery pressure greater than 25 mmHg, with various factors contributing to the pathogenesis of the disease, including higher levels of endothelin-1, decreased nitric oxide (NO) synthase expression, and inhibition of the prostacyclin pathway which leads to decreased relaxation and induced proliferation of pulmonary artery smooth muscle cells (PASMCs) (McLaughlin and McGoon, 2006).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
